The provided marketing language for Sabinsa’s Amla ingredient, Saberry®, should be carefully modified to align with dietary supplement regulations, specifically avoiding implications of disease treatment or prevention. Here’s a suggested revision:
“In a recent 90-day, multicentric randomized open label trial, Sabinsa’s Amla ingredient, Saberry®, was observed to support healthy blood sugar levels.
Saberry® is a unique, patented ingredient, distinctively characterized by its standardization with beta glucogallin, a Gallotannin compound, derived from Indian Gooseberry. This self-affirmed GRAS ingredient, consumed as a dietary supplement for over a decade, is known for its excellent taste profile and water solubility, making it an innovative choice for functional beverages.
The study, involving 126 subjects with a BMI ranging from 27-35, explored the effects of two different doses of Saberry® (1g and 2g) compared to a standard treatment group. The results indicated a supportive effect on maintaining healthy blood sugar levels, both fasting and postprandial, as well as beneficial impacts on lipid parameters such as LDL, VLDL, and total cholesterol. These observations were dose-dependent, with the 2g dosage showing a notable effect.
It’s important to note that while Saberry® has been associated with these health-supportive effects, it is not intended to diagnose, treat, cure, or prevent any disease.”
The research article may be found at Food Funct.,2022,13,9523-31.